A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Bendamustine; Cyclophosphamide; Obinutuzumab; Prednisone; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 20 Apr 2018 Planned End Date changed from 11 Sep 2021 to 27 Mar 2020.
    • 12 Dec 2017 An interim analysis of safety and efficacy data presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Dec 2017 Planned End Date changed from 15 Jan 2020 to 11 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top